Ponesimod
Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis. It is a sphingosine-1-phosphate receptor modulator. The most common side effects include upper respiratory tract infection, hepatic transaminase elevation, and hypertension. Ponesimod was approved for medical use in the United States in March 2021, and in the European Union in June 2021.
Adverse effects
Common adverse effects in studies were temporary bradycardia (slow heartbeat), usually at the beginning of the treatment, dyspnoea (breathing difficulties), and increased liver enzymes (without symptoms). No significant increase of infections was observed under ponesimod therapy. QT prolongation is detectable but was considered to be too low to be of clinical importance in a study.
Mechanism of action
Like fingolimod, which is already approved for the treatment of multiple sclerosis, ponesimod blocks the sphingosine-1-phosphate receptor. This mechanism prevents lymphocytes (a type of white blood cells) from leaving lymph nodes. Ponesimod is selective for subtype 1 of this receptor, S1P 1 .
Text derived from https://en.wikipedia.org/w/index.php?oldid=1333337768 under CC BY-SA 4.0; modifications have been made.